Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Objective: To evaluate clinicopathologic factors and adjuvant treatment effects on recurrence free (RFS) and overall survival (OS) in early stage uterine clear cell carcinoma (UCCC). Methods: Our retrospective review included central pathology confirmed stage I or II UCCC treated and/or followed between 2000 and 2016. Cases with pure or mixed histology with >50% UCCC were included. Data were analyzed using Kaplan-Meier method and Cox proportional hazards regressions. Results: 112 women were identified. Median age was 65.5 years (range 34–94). Most patients had mixed UCCC (61%), while 39% had pure UCCC. The majority of patients had stage IA UCCC (66%) versus stage IB (15%) or stage II (18%) disease. Adjuvant treatment included chemotherapy + radiation (26%), brachytherapy (27%), whole pelvic radiation (15%), chemotherapy alone (8%), and observation (24%). Thirty-eight (34%) women had recurrent disease. Median RFS was 4.32 years (95% CI 2.77–5.78). On multivariate analysis, age ≥70 (HR 2.48, 95% 1.28–4.81) and positive LVSI (HR 2.19, 95% CI 1.15–4.18) were associated with shorter RFS. Median OS was 9.8 years (95% CI 7.46–15.93). On multivariate analyses, age ≥70 (HR 3.57, 95% CI 1.64–7.74) and positive LVSI (HR 2.46, 95% CI 1.12–5.37) were associated with shorter OS. In this retrospective descriptive uncontrolled patient series, adjuvant treatment type did not impact RFS or OS. Conclusions: OS approaches 10 years for early stage UCCC patients. Women ≥70 years have worse PFS and OS regardless of treatment modality, encouraging consideration of quality of life implications when electing for adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)328-332
Number of pages5
JournalGynecologic oncology
Volume154
Issue number2
DOIs
StatePublished - Aug 2019

Keywords

  • Chemotherapy
  • Clear cell carcinoma
  • Endometrial cancer
  • Radiation

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

MD Anderson CCSG core facilities

  • Biostatistics Resource Group
  • Clinical Trials Office

Fingerprint

Dive into the research topics of 'Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience'. Together they form a unique fingerprint.

Cite this